A NOVEL MULTIPLEX ELISA ASSAY FOR SURVEILLING PATIENTS WITH A HISTORY OF BLADDER CANCER

Research Topic: Bladder Cancer

Study Title: A NOVEL MULTIPLEX ELISA ASSAY FOR SURVEILLING PATIENTS WITH A HISTORY OF BLADDER CANCER

Research Team:
Sima Porten, MD, MPH, Principal Investigator (PI)
Ada Sanchez, Clinical Research Coordinator

Sponsor: Cedars Sinai Medical Center, National Cancer Institute (NCI), Nonagen Bioscience Corp

Study Overview

This study is evaluating an investigational test designed to predict how well people with bladder cancer respond to bacillus Calmette-Guérin (BCG), a treatment that is placed directly into the bladder. Researchers will collect information from participants to determine whether this test can accurately identify which patients are most likely to benefit from BCG treatment. The findings may help improve treatment planning and guide more personalized care for people with bladder cancer in the future.

Who can join?

Green check mark
  • Must have intermediate or high rick NMIBC 
  • Must have all papillary tumors resected
  • Must be willing to sign study consent
  • Must be willing to provide urine specimen
  • Must be willing to allow tumor tissue storage for future use

What to Expect During the Study

clipboard
Research activities

Study participants donate urine specimens at 4 different timepoints (baseline, 4 weeks, 3 month and 6 month) and/or if they have recurrence. They are followed clinically as well.

Globe
Location

In person and remote

UCSF Mission Bay campus
 

Stick figures in a circle
How you can help
  • Participation in this study will help researchers evaluate whether an investigational test can identify which patients are most likely to respond to BCG therapy.
  • Participation in this study will help researchers determine whether the test can identify patients who may be at higher risk of their bladder cancer returning after BCG treatment.
  • Participation in this study will help advance the development of tools that may support more personalized treatment decisions and improve care for future patients with bladder cancer.

FAQ's

24 months

Study participants donate urine specimens at 4 different timepoints (baseline, 4 weeks, 3 month and 6 month) and/or if they have recurrence. They are followed clinically as well.

N/A

400

Contact us

Ada Sanchez, Clinical Research Coordinator
[email protected]

Print this page